scholarly journals A Brief Review on Spinocerebellar Ataxia and its Treatment

2020 ◽  
pp. 1-5
Author(s):  
Rahul Singh Dhariyal ◽  
◽  
Vishwadeepak Kimothi ◽  
Mohammad Asifb MohdImran ◽  
◽  
...  
Keyword(s):  
Spinocerebellar Ataxia ◽  
Autosomal Dominant ◽  
Trinucleotide Repeat ◽  
Genetic Disorder ◽  
The United States ◽  
Systemic Review ◽  
Chromosomal Locus ◽  
Causative Gene ◽  
Hereditary Ataxias ◽  
Global Prevalence

Ataxia is defined as a neurological sign including the lack of muscle movement coordination particularly of gait abnormality, talking changes, and also abnormality in eye actions. In ataxia, a part of nervous system is dysfunction which is also coordinate movement such as the cerebellum. In adults, ataxia can be acquired or genetic disorder. The Spinocerebellar ataxia is hereditary, progressive, degenerative, genetic disease or often fatel. There are no effective treatment and cure for Spinocerebellar ataxia (SCA). Spinocerebellar ataxia is a progressive disorders in which the cerebellum slowly degenerates. An average results estimated that 150,000 peoples in the United States have a diagnosis of Spinocerebellar ataxia (SCA) at any given time periods. Spinocerebellar ataxia (SCA) can affects anybody persons of at all ages. A current systemic review shows that the global prevalence of Spinocerebellar ataxia (SCA) is 3 in 100,000 people. However, a wide regional variation exists. SCA3 is common subtype around the world, SCA2 is additional prevalent in Cuba than SCA3 whilst SCA7 is the most frequent subtype in Venezuela due to strong founder’s effect. SCA6 is 1 of the most general ADCA in the North of England, with a global prevalence of 5.2/100,000.There are many different types of spinocerebellar ataxia (SCA) and each may have unique signs and symptoms. And these includes: Problems with coordination and balance (ataxia), Uncoordinated walk, poor hand eye coordination, Abnormal speech, Involuntary eye movement, Vision problems, Difficulty processing, Learning and remembering information. The hereditary ataxias are categorized by mode of inheritance and causative gene or chromosomal locus. The hereditary ataxias can be inherited in an autosomal dominant, autosomal recessive,or X-linked manner. Some types of SCA inherited in an autosomal dominant manner are caused by trinucleotide repeat expansions. A trinucleotide repeat is a segment of DNA that is repeated a number of times. It is normal for these repeats to exist and they typically do not cause any problems. Some Spinocerebellar ataxia SCAs remain unspecified and cannot be precisely diagnosed, but in the previous decades genetic testing has permissible precise identification of dozens of different SCAs and extra tests are being added each year. The spinocerebellar ataxia are classified SCA1 to SCA35for the treatment of SCA. There are no effective and cure treatment available for the spinocerebellar ataxia (SCA). But there are some methods; therapies and treatment are available which will be fruitful for the SCA. And these included the following: Meditation, Zolpidem, N-acetyl leucine, Rehabilitation

scholarly journals Identification of Novel Causal FBN1 Mutations in Pedigrees of Marfan Syndrome

2018 ◽  
Vol 2018 ◽  
pp. 1-8
Author(s):  
Yueli Wang ◽  
Xiaoyan Li ◽  
Rongjuan Li ◽  
Ya Yang ◽  
Jie Du
Keyword(s):  
Next Generation Sequencing ◽  
Marfan Syndrome ◽  
Cardiovascular Events ◽  
Autosomal Dominant ◽  
Genetic Disorder ◽  
Novel Mutations ◽  
Causative Gene ◽  
Fibrillin 1 ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing

Marfan syndrome (MFS) is an autosomal dominant genetic disorder of the connective tissue, typically characteristic of cardiovascular manifestations, valve prolapse, left ventricle enlargement, and cardiac failure. Fibrillin-1 (FBN1) is the causative gene in the pathogenesis of MFS. Patients with different FBN1 mutations often present more considerable phenotypic variation. In the present study, three affected MFS pedigrees were collected for genetic analysis. Using next-generation sequencing (NGS) technologies, 3 novel frameshift pathogenic mutations which are cosegregated with affected subjects in 3 pedigrees were identified. These novel mutations provide important diagnostic and therapeutic insights for precision medicine in MFS, especially regarding the lethal cardiovascular events.

scholarly journals Serum neurofilament light chain as a severity marker for spinocerebellar ataxia

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hye-Rim Shin ◽  
Jangsup Moon ◽  
Woo-Jin Lee ◽  
Han Sang Lee ◽  
Eun Young Kim ◽  
...  
Keyword(s):  
Spinocerebellar Ataxia ◽  
Disease Duration ◽  
Trinucleotide Repeat ◽  
Neuronal Damage ◽  
Demographic Data ◽  
Brain Magnetic Resonance Imaging ◽  
Clinical Severity ◽  
P Value ◽  
Repeat Number ◽  
Neurofilament Light

AbstractSince the serum neurofilament light (NfL) chain is known as a promising biomarker in neurodegenerative diseases, we aimed to evaluate serum NfL as a biomarker indicating neuronal damage in autosomal-dominant (AD) spinocerebellar ataxia (SCA). We reviewed patients diagnosed with AD SCA in the outpatient clinic of Seoul National University Hospital’s (SNUH) Department of Neurology between May and August of 2019. We reviewed the demographic data, clinical characteristics, Scale for the Assessment and Rating of Ataxia (SARA) score, and brain magnetic resonance imaging (MRI) scans. The serum NfL was measured by electrochemiluminescence (ECL) immunoassay. Forty-nine patients with AD SCA were reviewed and their serum NfL level was determined. The median serum NfL level (109.5 pg/mL) was higher than control (41.1 pg/mL) (p-value < 0.001). Among the AD SCA patients, there was a positive correlation between the serum NfL level and the trinucleotide repeat number (r = 0.47, p-value = 0.001), disease duration (r = 0.35, p-value = 0.019), disease duration/age × trinucleotide repeat number (r = 0.330, p-value = 0.021), and SARA score (n = 33; r = 0.37, p-value = 0.033). This study shows that serum NfL is elevated in AD SCA patients and correlates with clinical severity.

scholarly journals A Case Report of a Prenatally Missed Mowat-Wilson Syndrome With Isolated Corpus Callosum Agenesis

2021 ◽  
Vol 8 ◽  
pp. 2329048X2110065
Author(s):  
Nesrin Şenbil ◽  
Zeynep Arslan ◽  
Derya Beyza Sayın Kocakap ◽  
Yasemin Bilgili
Keyword(s):  
Corpus Callosum ◽  
Autosomal Dominant ◽  
Genetic Disorder ◽  
Gene Mutations ◽  
Hirschsprung Disease ◽  
Agenesis Of Corpus Callosum ◽  
Whole Exome ◽  
Congenital Cardiac Anomalies ◽  
History Of ◽  
Gene Mutation Analysis

Mowat–Wilson syndrome (MWS) is an autosomal dominant genetic disorder caused by ZEB2 gene mutations, manifesting with unique facial characteristics, moderate to severe intellectual problems, and congenital malformations as Hirschsprung disease, genital and ophthalmological anomalies, and congenital cardiac anomalies. Herein, a case of 1-year-old boy with isolated agenesis of corpus callosum (IACC) in the prenatal period is presented. He was admitted postnatally with Hirschsprung disease (HSCR), hypertelorism, uplifted earlobes, deeply set eyes, frontal bossing, oval-shaped nasal tip, ‘‘M’’ shaped upper lip, opened mouth and prominent chin, and developmental delay. Hence, MWS was primarily considered and confirmed by the ZEB2 gene mutation analysis. His karyotype was normal. He had a history of having a prenatally terminated brother with similar features. Antenatally detected IACC should prompt a detailed investigation including karyotype and microarray; even if they are normal then whole exome sequencing (WES) should be done.

scholarly journals Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes

2019 ◽  
Vol 8 (4) ◽  
pp. 493 ◽  
Author(s):  
Wylezinski ◽  
Gray ◽  
Polk ◽  
Harmata ◽  
Spurlock
Keyword(s):  
Healthcare System ◽  
Inflammatory Diseases ◽  
The United States ◽  
Economic Benefits ◽  
Systemic Review ◽  
Best Interest ◽  
Delayed Treatment ◽  
Inflammatory Conditions ◽  
Slow Development ◽  
The U.S

Healthcare expenditures in the United States are growing at an alarming level with the Centers for Medicare and Medicaid Services (CMS) projecting that they will reach $5.7 trillion per year by 2026. Inflammatory diseases and related syndromes are growing in prevalence among Western societies. This growing population that affects close to 60 million people in the U.S. places a significant burden on the healthcare system. Characterized by relatively slow development, these diseases and syndromes prove challenging to diagnose, leading to delayed treatment against the backdrop of inevitable disability progression. Patients require healthcare attention but are initially hidden from clinician’s view by the seemingly generalized, non-specific symptoms. It is imperative to identify and manage these underlying conditions to slow disease progression and reduce the likelihood that costly comorbidities will develop. Enhanced diagnostic criteria coupled with additional technological innovation to identify inflammatory conditions earlier is necessary and in the best interest of all healthcare stakeholders. The current total cost to the U.S. healthcare system is at least $90B dollars annually. Through unique analysis of financial cost drivers, this review identifies opportunities to improve clinical outcomes and help control these disease-related costs by 20% or more.

Spinocerebellar ataxia type 28: A novel autosomal dominant cerebellar ataxia characterized by slow progression and ophthalmoparesis

2008 ◽  
Vol 7 (2) ◽  
pp. 184-188 ◽  
Author(s):  
Caterina Mariotti ◽  
Alfredo Brusco ◽  
Daniela Di Bella ◽  
Claudia Cagnoli ◽  
Marco Seri ◽  
...  
Keyword(s):  
Cerebellar Ataxia ◽  
Spinocerebellar Ataxia ◽  
Autosomal Dominant ◽  
Autosomal Dominant Cerebellar Ataxia ◽  
Spinocerebellar Ataxia Type ◽  
Slow Progression

scholarly journals Malaria continues to select for sickle cell trait in Central Africa

2015 ◽  
Vol 112 (22) ◽  
pp. 7051-7054 ◽  
Author(s):  
Eric Elguero ◽  
Lucrèce M. Délicat-Loembet ◽  
Virginie Rougeron ◽  
Céline Arnathau ◽  
Benjamin Roche ◽  
...  
Keyword(s):  
Sickle Cell ◽  
Sickle Cell Trait ◽  
Genetic Disorder ◽  
Central Africa ◽  
The United States ◽  
Malaria Prevalence ◽  
Current Data ◽  
World Health ◽  
Human Populations ◽  
Health Organization

Sickle cell disease (SCD) is a genetic disorder that poses a serious health threat in tropical Africa, which the World Health Organization has declared a public health priority. Its persistence in human populations has been attributed to the resistance it provides to Plasmodium falciparum malaria in its heterozygous state, called sickle cell trait (SCT). Because of migration, SCT is becoming common outside tropical countries: It is now the most important genetic disorder in France, affecting one birth for every 2,400, and one of the most common in the United States. We assess the strength of the association between SCT and malaria, using current data for both SCT and malaria infections. A total of 3,959 blood samples from 195 villages distributed over the entire Republic of Gabon were analyzed. Hemoglobin variants were identified by using HPLCy (HPLC). Infections by three species of Plasmodium were detected by PCR followed by sequencing of a 201-bp fragment of cytochrome b. An increase of 10% in P. falciparum malaria prevalence is associated with an increase by 4.3% of SCT carriers. An increase of 10 y of age is associated with an increase by 5.5% of SCT carriers. Sex is not associated with SCT. These strong associations show that malaria remains a selective factor in current human populations, despite the progress of medicine and the actions undertaken to fight this disease. Our results provide evidence that evolution is still present in humans, although this is sometimes questioned by scientific, political, or religious personalities.

Sign in / Sign up

Export Citation Format

Share Document